SOURCE: Amazon Biotech, Inc.

June 06, 2007 09:56 ET

Amazon Biotech, Inc. Announces Symbol Change to "AMZO"

Modest Reverse Split Necessary for Financing for Clinical Trials of HIV Drug

NEW YORK, NY--(Marketwire - June 6, 2007) - Amazon Biotech, Inc. (OTCBB: AMZB) (OTCBB: AMZO) (FRANKFURT: B2D) ("Company") today announced that the Company's new symbol is AMZO.

Amazon Biotech recently executed a three-for-one reverse split in preparation for a pending financing for clinical trials of the company's immunomodulator drug, AMZ0026, for the treatment of HIV/AIDS. The company's all-natural whole plant pharmaceutical drug is expected to enter Phase I/II clinical trials upon closing on a financing.

Mechael Kanovsky, CEO of Amazon Biotech, said, "Although it has taken longer to obtain the financing necessary to conduct our clinical trials in preparation for an eventual filing with the US Federal Drug Administration (FDA), we look forward to securing the financing soon and rapidly progress once the trials begin. In addition, we have an FDA-approved trial protocol ready for the recruitment of patients."

The approved protocol is designed to test the safety, immunological and antiviral effects of AMZ0026, Amazon Biotech's anti-HIV parent formula. The double-blind, placebo-controlled clinical trial design involves 32 non-symptomatic HIV subjects who have yet to be treated with Highly Active Anti-Retroviral Therapy (HAART). The six-month study will include the monitoring of T Cell increases and HIV plasma viral load decreases.

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical drug company, primarily developing immunomodulator drugs. AMZ0026 is the Company's first such drug to be used for the treatment of HIV/AIDS. The Company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of partnering with a major pharmaceutical company. Amazon Biotech specializes in natural whole plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

Additional information and previous announcements on Amazon Biotech may be found at:

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof. Commitment to do a study does not represent that the Company has FDA approval on the protocol to start the study.

Contact Information